October 14th, 2025 | 07:15 CEST
Momentum plays with a new wave: Almonty Industries and Rheinmetall – what is Gerresheimer doing?
The trade dispute between the US and China appears to be entering the next round. Late last week, US President Trump announced his intention to impose additional punitive tariffs of 100% on Chinese goods. The measures are expected to take effect by November at the latest. This follows China's decision to tighten export controls on certain technologies and raw materials. China holds many critical raw materials and is gradually restricting their export. While consumers face major challenges in view of the shortage of demand and rising prices, producers of these raw materials are among the stock market favorites.
time to read: 3 minutes
|
Author:
Carsten Mainitz
ISIN:
ALMONTY INDUSTRIES INC. | CA0203987072 , RHEINMETALL AG | DE0007030009 , GERRESHEIMER AG | DE000A0LD6E6
Table of contents:
Author
Carsten Mainitz
The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.
Tag cloud
Shares cloud
Almonty Industries – In a strong position!
Almonty Industries is benefiting from this situation. The Canadian company is set to start tungsten production at its Sangdong mine in South Korea this year and, through further expansion stages, will soon become the largest tungsten producer outside China. Tungsten is in high demand across many industries, especially in defense, due to its exceptional hardness and heat resistance.
With a deposit like Sangdong, the Western world can take an important step toward greater security of supply in the face of China's dominance. Almonty already has extensive experience and expertise in the construction and operation of tungsten mines. The Canadians have impressively demonstrated this through their many years of activity in Portugal. Given the sharp rise in tungsten prices in recent months, many of the previous assumptions are now proving to be too conservative.
The Company is also considering strategic acquisitions. It is examining takeover candidates in the US with the aim of establishing a production foothold in North America. The US, in particular, has a keen interest in critical raw materials. Almonty already has a number of long-term offtake agreements in place. At the same time, the Company is advancing work on a second critical raw material at the Sangdong site, molybdenum, with plans to define a resource and tap into another highly sought-after market.
Despite the excellent share price performance in recent months, Almonty Industries continues to offer good prospects. The share currently has a 2027 P/E ratio of 15, which is moderate given the growth momentum. The market capitalization is an impressive CAD 2.4 billion.
Rheinmetall – German Armed Forces place large order
The defense contractor's order books appear to be filling up further. According to Handelsblatt, the German Armed Forces are planning to place a large order for over 600 Skyranger air defense systems this year. The volume, including the necessary vehicles, is expected to amount to more than EUR 9 billion.
Analysts rate the stock as a "Buy" overall, especially as the shares are correcting somewhat from their all-time high, which was in the region of EUR 2,000. US bank JPMorgan recently rated Rheinmetall as "Overweight" with a price target of EUR 2,250. Analysts expect a mediocre Q3, but see a strong final quarter. Facts will be revealed on November 6, when the Company publishes its key figures for the third quarter.
Gerresheimer – Third profit warning in the current fiscal year!
Once again, Gerresheimer has made headlines with disappointing news. At the end of last week, the Düsseldorf-based company shocked the markets by issuing its third downward revision of annual targets for the fiscal year ending in November. The share price plunged again and has now fallen below the EUR 30 mark.
As demand from cosmetics and pharmaceutical companies did not pick up as hoped, CEO Dietmar Siemssen felt compelled to take this step. The Company announced a "comprehensive transformation program" aimed at improving operational performance and cash flow through cost-cutting measures and selective investments. Most recently, JPMorgan and Deutsche Bank lowered their price targets for the stock to EUR 46 and EUR 34, respectively.
Even the positive news that followed failed to lift sentiment: The US Food and Drug Administration (FDA) has approved one of Gerresheimer's products for the treatment of edema in congestive heart failure, with market launch planned for the end of 2025. Investors, however, remain unimpressed.
Defense stocks and producers of critical raw materials will continue to remain favorites among investors. Demand and industry trends are clearly positive. Almonty's role as a key supplier of essential raw materials is increasingly being recognized by the market, and the upward trend shows no signs of slowing. The fundamental valuation continues to offer room for growth. Gerresheimer, in contrast, can be classified as a turnaround candidate and requires patience and a long-term perspective from investors.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
